HOME > BUSINESS
BUSINESS
- Chugai Sales Up 8.4% Due to Increase in Cancer Treatment, Overseas Sales
July 26, 2013
- Safety of Atopic Dermatitis Treatment Confirmed in PI Study in Japan: AnGes MG
July 26, 2013
- OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines
July 26, 2013
- Can Generic Drug Industry Achieve “Zero Supply Disruptions” by FY2015? 30 Products –Largest Ever– from 14 Companies Experience Shortage in 2012
July 26, 2013
- Toho Pharmaceutical’s New Logistics Center in Hyogo Begins Operations
July 25, 2013
- Janssen Provides Free Simplified Dementia Screening Tool to Medical Institutions
July 25, 2013
- Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
- Novartis Launches Diovan OD Tablets, Sales Reps Find Promotion Difficult
July 24, 2013
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
- Toho University Prof. Nakamura Says Prasugrel Promising in Preventing Platelet Clotting
July 22, 2013
- AD Treatment Lu AE58054 Improves Cognitive Performance in PII Study: Otsuka Pharmaceutical
July 22, 2013
- AD Biomarker TOMM40 Favorable in Detecting AD Risk: Takeda
July 19, 2013
- Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health
July 19, 2013
- Teribone’s Sales Growing Fast, Owing to High Demand of Drugs Promoting Bone Formation: Asahi Kasei Pharma President
July 19, 2013
- 60% Generic Share Target Is Highly Achievable: Daiichi Sankyo Espha President Yoshiwaka
July 19, 2013
- Novartis to Share Ex-Employee Hearing Info, Says “Gravely Concerned” about Media Reports
July 18, 2013
- Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
- BIKEN, JPRI to Merge in April
July 18, 2013
- MTPC to Strengthen Vaccine Development through Merger with Canadian Biotech Company Medicago
July 18, 2013
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
